Vancouver, British Columbia and Rehovot, Israel–(Newsfile Corp. – August 24, 2023) – BioHarvest Sciences Inc. (CSE: BHSC) (OTCQB: CNVCF) (“BioHarvest” or the “Company”) announces that it is hosting the Q2 Performance Update Presentation on Wednesday, September 6, 2023, at 11:30 am PST | 2:30 pm EST. The interactive session will be hosted by CEO Ilan Sobel.
Mr. Sobel will discuss the Q2 financials announced this coming August 30th, and he will provide additional information regarding major VINIA marketing programs and upcoming new product pipeline. Following the presentation, there will be a live question and answer session. All media and investors are invited to pre-register. For any questions regarding the event, please contact info@bioharvest.com.
Link to register: https://us02web.zoom.us/webinar/register/WN_-GLrw-xJRq-QItHf6Hvnyg#/registration
“I look forward to meeting with our shareholder partners on September 6, and to sharing my enthusiasm about the prospects of BioHarvest and the achievements being made,” stated CEO Ilan Sobel. “I will shed some more light on the Q2 results scheduled to be released at the end of August, and I will offer an outlook into the key growth drivers of the company.”
About BioHarvest Sciences Inc.
BioHarvest Sciences Inc. (CSE: BHSC) is a fast-growing Biotech firm listed on the Canadian Securities Exchange. BioHarvest has developed a patented bio-cell growth platform technology capable of growing the active and beneficial ingredients in fruit and plants, at an industrial scale, without the need to grow the plant itself. BioHarvest is currently focused on leveraging its botanical synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions, within two major business verticals – nutraceutical health and wellness products such as dietary supplements, and development of plant cell-based Active Pharmaceutical Ingredients (API’s) that focus on specific medical indications. Visit: www.bioharvest.com.
BioHarvest Sciences Inc.
Ilan Sobel, Chief Executive Officer
For further information, please contact:
Dave Ryan, VP Investor Relations & Director
Phone: 1 (604) 622-1186
Email: dave@bioharvest.com
Forward-Looking Statements
Information set forth in this news release might include forward-looking statements that are based on management’s current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. There is no assurance that we will achieve our objective of making our products available in multiple markets.
All forward-looking statements are inherently uncertain and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. BHSC does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures.
Neither the Canadian Securities Exchange nor its Regulation Services Provider accept responsibility for the adequacy or accuracy of this release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/178238
SINGAPORE, June 23, 2024 /PRNewswire/ -- Singapore-headquartered Juniper Biologics Pte Ltd (Juniper), a leading healthcare…
FRONTIER2 data presented at ISTH 2024 showed that up to 95% of people, who had…
Pemvidutide elicited significant weight loss and decreases in pro-inflammatory serum lipids associated with atherogenesis and…
TAIPEI, June 22, 2024 /PRNewswire/ -- The prestigious 2024 Tang Prize Laureates have been announced,…
Afrezza® Afrezza® (insulin human) Inhalation Powder. Study proves inhaled insulin is as effective as usual…
PURCHASE, NY, June 21, 2024 (GLOBE NEWSWIRE) -- Teladoc Health (NYSE: TDOC), the global leader…